EUCTR2013-003503-19-DE进行中（未招募）1 期
Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy - IMPULSE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Mologen AG
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients with extensive disease SCLC = 18 years of age receiving platinum-based first-line chemotherapy;
- •2. Extensive disease SCLC confirmed by a pathologist, on the basis of
- •histology of SCLC or mixed histology of SCLC, or a cytological diagnosis if
- •histology cannot be obtained;
- •3. Completion of 4 cycles of first-line therapy with a platinum-based regimen and no other prior chemotherapy;
- •4. Documented evidence of tumor response (PR or CR) as assessed by the investigator at the end of the fourth cycle of platinum-based first-line chemotherapy using CT or magnetic resonance imaging (MRI) scan;
- •5. Brain metastases are allowed only after cranial irradiation, if asymptomatic and not requiring continuous treatment with steroids or anticonvulsants. MRI of the brain should be performed in all patients at Screening;
- •6. ECOG performance status 0 or 1;
- •7. Adequate organ function with total bilirubin, lactate dehydrogenase [LDH], alkaline phosphatase [AP], albumin, creatinine, urea, electrolytes, and coagulation parameters = 1.5 × upper limit of normal (ULN), and with aspartate aminotransferase [AST] and ALT = 2.5 × ULN in the absence of liver metastases or = 5.0 × ULN in the presence of liver metastases;
- •8. Adequate hematological parameters: absolute neutrophil count = 1.0 × 109/L; platelet count = 80 × 109/L; leukocyte count = 2.0 × 109/L; lymphocytes = 0.8 × 109/L; hemoglobin = 9.0 g/dL or 5.59 mmol/L;
- •9. Male patients who have had vasectomy, and female patients who are not of childbearing potential (i.e. who are post-menopausal for at least 24 consecutive months or who have undergone surgical sterilization [hysterectomy, bilateral tubal ligation, or bilateral oophorectomy]). Male and female patients with reproductive potential can be included if they are using an effective means of contraception with a failure rate of less than 1% per year throughout the study, e.g. established use of oral, implanted, or injected hormonal contraceptives; placement of intra-uterine device or intra-uterine system; or use of barrier methods such as condom or diaphragm together with spermicide product;
- •10. Negative serum pregnancy test in women of childbearing potential;
- •11. Signed informed consent form (ICF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Patients with no evidence of tumor response (PR or CR) at the end of the fourth cycle of platinum-based chemotherapy;
- •2. Clinically significant concomitant diseases or conditions, which, in opinion of the investigator, would lead to an unacceptable risk for the patient to participate in the study;
- •3. Prior or current other malignancy, except adequately treated superficial bladder cancer, basal or squamous cell carcinoma of the skin, or other cancer for which the patient has been disease free for more than 3 years;
- •4. History of carcinomatous meningitis;
- •5. Prior or current paraneoplastic syndrome related to SCLC;
- •6. Active or uncontrolled infections at the time of randomization;
- •7. Severe anemia requiring repeated blood cell transfusion;
- •8. History of autoimmune disease or immune deficiency;
- •9. Known hypersensitivity to oligonucleotides or excipients of the formulation;
- •10. Pregnant and/or nursing;
- •11. Chronic systemic immune therapy or immunosuppressant medication
- •other than steroids within the last 6 weeks prior to study treatment. If
- •the patient receives systemic steroids at the time of Screening, the dose
- •of systemic steroids should gradually be reduced before start of
- •treatment in the experimental arm;
- •12. Concurrent use of molecular targeted therapy;
- •13. HIV seropositivity or active hepatitis B or C infection;
- •14. Planned major surgery during the study, except for thoracotomy;
- •15. Participation in another clinical study with other investigational drugs within 28 days prior to study treatment, or treatment with any anti-cancer investigational drug within 12 months prior to study treatment;
- •16. Vaccination within 1 month prior to study treatment;
- •17. Any medical, mental, psychological or psychiatric condition that in the opinion of the investigator would not permit the patient to complete the study or understand the patient information;
- •18. Presence of drug and/or alcohol abuse.
研究者
相似试验
进行中（未招募）
1 期
Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line TherapySmall Cell Lung CancerEUCTR2013-003503-19-BEMologen AG100
进行中（未招募）
1 期
Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line TherapyMedDRA version: 17.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Small Cell Lung CancerEUCTR2013-003503-19-ESMologen AG110
进行中（未招募）
1 期
Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line TherapyMedDRA version: 18.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Small Cell Lung CancerEUCTR2013-003503-19-ATMologen AG100
已完成
3 期
Randomized Phase III trial: Maintenance therapy with the monoclonal chimeric antibody rituximab compared to observation in patients with CD20+ B-cell Non-Hodgkins lymphomaCancerLymphomaB-cell lymphomaISRCTN74547745niversity of Heidelberg (Germany) and Roche (Switzerland)174
尚未招募
不适用
A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancerNeoplasmsKCT0008619ational Cancer Center138